JP7133225B2 - 治療用多標的コンストラクトおよびその使用 - Google Patents

治療用多標的コンストラクトおよびその使用 Download PDF

Info

Publication number
JP7133225B2
JP7133225B2 JP2019517069A JP2019517069A JP7133225B2 JP 7133225 B2 JP7133225 B2 JP 7133225B2 JP 2019517069 A JP2019517069 A JP 2019517069A JP 2019517069 A JP2019517069 A JP 2019517069A JP 7133225 B2 JP7133225 B2 JP 7133225B2
Authority
JP
Japan
Prior art keywords
seq
peptide
toxin
peptides
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019517069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020501513A (ja
JP2020501513A5 (cg-RX-API-DMAC7.html
Inventor
ムラッド,イラン
イツハキ,ハナーン
Original Assignee
エーイービーアイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーイービーアイ リミテッド filed Critical エーイービーアイ リミテッド
Publication of JP2020501513A publication Critical patent/JP2020501513A/ja
Publication of JP2020501513A5 publication Critical patent/JP2020501513A5/ja
Application granted granted Critical
Publication of JP7133225B2 publication Critical patent/JP7133225B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019517069A 2016-09-29 2017-09-27 治療用多標的コンストラクトおよびその使用 Active JP7133225B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662401192P 2016-09-29 2016-09-29
US201662401195P 2016-09-29 2016-09-29
US62/401,192 2016-09-29
US62/401,195 2016-09-29
PCT/IL2017/051094 WO2018061004A1 (en) 2016-09-29 2017-09-27 Therapeutic multi-targeting constructs and uses thereof

Publications (3)

Publication Number Publication Date
JP2020501513A JP2020501513A (ja) 2020-01-23
JP2020501513A5 JP2020501513A5 (cg-RX-API-DMAC7.html) 2020-11-12
JP7133225B2 true JP7133225B2 (ja) 2022-09-08

Family

ID=61763358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019517069A Active JP7133225B2 (ja) 2016-09-29 2017-09-27 治療用多標的コンストラクトおよびその使用

Country Status (8)

Country Link
US (2) US11739163B2 (cg-RX-API-DMAC7.html)
EP (1) EP3518953A4 (cg-RX-API-DMAC7.html)
JP (1) JP7133225B2 (cg-RX-API-DMAC7.html)
CN (1) CN109789183A (cg-RX-API-DMAC7.html)
AU (2) AU2017333442A1 (cg-RX-API-DMAC7.html)
CA (1) CA3037261A1 (cg-RX-API-DMAC7.html)
IL (1) IL265236B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018061004A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3518953A4 (en) * 2016-09-29 2020-10-28 Aebi Ltd. THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND THEIR USES
US20210198319A1 (en) * 2017-09-27 2021-07-01 Aebi Ltd. Cytotoxic peptides and conjugates thereof
KR102268983B1 (ko) 2019-09-11 2021-06-24 경북대학교 산학협력단 엔도테린 수용체 억제제에 의한 엑소좀 분비 억제 또는 pd-l1 발현 억제 용도
CN112252362A (zh) * 2020-10-10 2021-01-22 无锡市市政设施建设工程有限公司 基于bim实现地铁车站主体结构盘扣支架搭设的方法
CN121494980A (zh) * 2025-12-12 2026-02-10 北京大学第一医院(北京大学第一临床医学院) 抗胃泌素抗体及其杂交瘤细胞株和应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524598A (ja) 2003-03-03 2007-08-30 ダイアックス、コープ HGFレセプター(cMet)を特異的に結合するペプチドおよびその使用
JP2009518025A (ja) 2005-12-06 2009-05-07 ドマンティス リミテッド 細胞表面標的に対して結合特異性を有する二重特異性リガンドおよびその使用方法
US20100151003A1 (en) 2006-12-21 2010-06-17 Mohit Trikha Egfr binding peptides and uses thereof
JP2010154842A (ja) 2008-12-03 2010-07-15 Koji Kawakami Egfrを標的にした新規抗がんキメラペプチド
JP2011517314A (ja) 2008-02-14 2011-06-02 ブリストル−マイヤーズ スクイブ カンパニー Egfrに結合する操作されたタンパク質に基づく標的化された治療薬
JP2015509501A (ja) 2012-02-23 2015-03-30 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 剤を細胞へ送達するための改変型微生物毒素受容体
WO2015195721A1 (en) 2014-06-16 2015-12-23 Purdue Research Foundation Compositions and methods for treating cancer
JP2016512508A (ja) 2013-03-12 2016-04-28 バイオコン・リミテッド 融合免疫調節タンパク質及びその生産方法
JP2016526892A (ja) 2013-07-18 2016-09-08 ユートロピクス ファーマシューティカルズ, インコーポレイテッド 示差的bh3ミトコンドリアプロファイリング

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058865A1 (en) 2001-11-26 2004-03-25 Danishefsky Samuel J Homing peptide multimers, their preparation and uses
WO2005090393A2 (en) 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
DK1915617T3 (da) 2005-07-21 2011-11-21 Aebi Ltd Fremgangsmåder og sammensætninger til identifikation af et peptid, der har en intermolekylær interaktion med et interessemål
ES2544954T3 (es) 2006-02-14 2015-09-07 Universita' Degli Studi Di Siena Péptidos multiméricos ramificados para diagnóstico y terapia de tumores
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
CA2697922A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
EP2352522A4 (en) 2008-11-06 2014-03-05 Univ Washington BISPECIFIC AUXILIARIES FOR INTRA-CELLULAR RELEASE
US8741839B2 (en) 2009-01-18 2014-06-03 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin
US9321820B2 (en) 2009-10-14 2016-04-26 The Regents Of The University Of Colorado Compositions and methods for treating bladder cancer
ES2983470T3 (es) 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
DK2714738T3 (en) * 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
PL3489254T3 (pl) 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
JP6103832B2 (ja) 2012-06-25 2017-03-29 Hoya株式会社 Egfr結合性ペプチド
WO2015023979A1 (en) 2013-08-16 2015-02-19 Equip, Llc Discrete peg constructs
EP3518953A4 (en) * 2016-09-29 2020-10-28 Aebi Ltd. THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND THEIR USES
US20210198319A1 (en) 2017-09-27 2021-07-01 Aebi Ltd. Cytotoxic peptides and conjugates thereof
US20200339629A1 (en) 2019-04-24 2020-10-29 Aebi Ltd. Therapeutic constructs comprising cmet binding peptides

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524598A (ja) 2003-03-03 2007-08-30 ダイアックス、コープ HGFレセプター(cMet)を特異的に結合するペプチドおよびその使用
JP2009518025A (ja) 2005-12-06 2009-05-07 ドマンティス リミテッド 細胞表面標的に対して結合特異性を有する二重特異性リガンドおよびその使用方法
US20100151003A1 (en) 2006-12-21 2010-06-17 Mohit Trikha Egfr binding peptides and uses thereof
JP2011517314A (ja) 2008-02-14 2011-06-02 ブリストル−マイヤーズ スクイブ カンパニー Egfrに結合する操作されたタンパク質に基づく標的化された治療薬
JP2010154842A (ja) 2008-12-03 2010-07-15 Koji Kawakami Egfrを標的にした新規抗がんキメラペプチド
JP2015509501A (ja) 2012-02-23 2015-03-30 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 剤を細胞へ送達するための改変型微生物毒素受容体
JP2016512508A (ja) 2013-03-12 2016-04-28 バイオコン・リミテッド 融合免疫調節タンパク質及びその生産方法
JP2016526892A (ja) 2013-07-18 2016-09-08 ユートロピクス ファーマシューティカルズ, インコーポレイテッド 示差的bh3ミトコンドリアプロファイリング
WO2015195721A1 (en) 2014-06-16 2015-12-23 Purdue Research Foundation Compositions and methods for treating cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Angew. Chem. Int. Ed., 2015, Vol.54, pp.11760-11764
Asian J. Pharm. Sci., Available online 2015.09.14, Vol.11, pp.337-348
Cancer Lett., 2014, Vol.351, pp.13-22
Eur. J. Cancer, 2011, Vol.47, pp.773-783
ファルマシア, 2009, Vol.45, No.9, pp.923-924

Also Published As

Publication number Publication date
EP3518953A1 (en) 2019-08-07
AU2017333442A1 (en) 2019-04-04
JP2020501513A (ja) 2020-01-23
US20240002547A1 (en) 2024-01-04
AU2022221434A1 (en) 2022-10-06
US11739163B2 (en) 2023-08-29
EP3518953A4 (en) 2020-10-28
IL265236B1 (en) 2023-07-01
CN109789183A (zh) 2019-05-21
US20190225711A1 (en) 2019-07-25
CA3037261A1 (en) 2018-04-05
IL265236A (en) 2019-05-30
IL265236B2 (en) 2023-11-01
WO2018061004A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
US20240002547A1 (en) Therapeutic multi-targeting constructs and uses thereof
JP6722134B2 (ja) セリンプロテアーゼ分子および療法
CN103566377A (zh) 癌症的靶向免疫治疗
KR102224965B1 (ko) 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
JP2021514661A (ja) サイトカインに連結させたecm親和性ペプチドを用いてがんを処置するための方法および組成物
CN102238965A (zh) 选择性抗癌嵌合肽
US20210054047A1 (en) Novel anticancer fusion protein and use thereof
CN111164093A (zh) 去势抵抗性前列腺癌
KR20160064726A (ko) 세포 투과 펩타이드-항암제 접합체 및 이를 포함하는 암 치료용 조성물
KR20220015375A (ko) Sephb4-hsa 융합 단백질을 이용한 암의 치료
EP3068797A1 (en) Epha3 and multi-valent targeting of tumors
JP2023145635A (ja) 免疫調節特性を有するペプチド
JP7680375B2 (ja) コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物
CN103347514B (zh) Fgfr1胞外域组合疗法
US11833204B2 (en) Visible light-activatable nanoparticles for cancer immunotherapy and use thereof
JP2010509241A (ja) 膜貫通ペプチドからなる自己凝集性ナノ粒子および抗癌剤の特異的腫瘍内送達のためのその利用
US20200339629A1 (en) Therapeutic constructs comprising cmet binding peptides
KR102831503B1 (ko) 암 예방 또는 치료를 위한 알부민 결합 전구약물, 이를 포함하는 약학 조성물
US20210198319A1 (en) Cytotoxic peptides and conjugates thereof
KR20250096752A (ko) 세포 표적화 구성체 및 그 용도
KR20160069667A (ko) 상피성장인자 수용체를 표적으로 하는 신규 항암제
KR102726136B1 (ko) Pd-l1 결합 펩타이드 2를 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도
KR20260007595A (ko) 다중 표적 약물 접합체 및 암 치료를 위한 이의 용도
CN114796471A (zh) 青蒿素类化合物与靶向nkg2d配体的car-t细胞联合制备治疗恶性肿瘤的药物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200928

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220822

R150 Certificate of patent or registration of utility model

Ref document number: 7133225

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250